Indication

As a single agent, for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and / or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.

Medicine details

Medicine name:
trastuzumab emtansine (Kadcyla)
SMC ID:
SMC2298
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
07 December 2020
SMC meeting date:
03 November 2020
Patient group submission deadline:
07 September 2020